TARCEVA® (erlotinib)

Drug TARCEVA® erlotinib Tarceva Overview Tarceva is a cancer medicine used in non‑small-cell lung cancer (NSCLC) that is advanced (the cancer has started to spread) or metastatic (it has already spread to other parts of the body). It is used for: previously untreated patients whose cancer cells have certain changes (‘activating mutations’) in the gene […]

SUTENT® (sunitinib)

Drug SUTENT® sunitinib Sutent Overview This is a summary of the European public assessment report (EPAR) for Sutent. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Sutent. How is Sutent used? Treatment with Sutent […]

ONIVYDE PEGYLATED LIPOSOMAL® (irinotecan hydrochloride trihydrate)

Drug ONIVYDE PEGYLATED LIPOSOMAL® Pembrolizumab Onivyde pegylated liposomal Overview Onivyde is a cancer medicine that is used to treat a form of pancreatic cancer called metastatic adenocarcinoma of the pancreas. Metastatic means that the cancer has spread to other parts of the body. Onivyde is used together with 5-fluorouracil and leucovorin (two other cancer medicines) […]

AFINITOR® (everolimus)

Drug AFINITOR® everolimus Afinitor Overview Afinitor is a cancer medicine used to treat the following cancers: breast cancer that is advanced (has started to spread) in women who have been through their menopause. Afinitor is used in breast cancer that is ‘hormone receptor-positive’ (when the cancer cells have oestrogen receptors on their surface) and ‘HER2/neu […]

XERMELO® (telotristat ethyl)

Drug XERMELO® telotristat ethyl Xermelo Overview This is a summary of the European public assessment report (EPAR) for Xermelo. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Xermelo. For practical information about using […]